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Abstract
Background: Evidence suggests that rheumatoid arthritis (RA) may enhance or reduce the progression of
Alzheimer’s disease (AD). The present study was performed to directly explore the effects of collagen-induced
rheumatoid arthritis (CIA) on amyloid plaque formation, microglial activation, and microvascular pathology in the
cortex and hippocampus of the double transgenic APP/PS1 mouse model for AD. Wild-type or APP/PS1 mice that
received type II collagen (CII) in complete Freund’s adjuvant (CFA) at 2 months of age revealed characteristics of
RA, such as joint swelling, synovitis, and cartilage and bone degradation 4 months later. Joint pathology was
accompanied by sustained induction of IL-1b and TNF-a in plasma over 4 weeks after administration of CII in CFA.
Results: CIA reduced levels of soluble and insoluble amyloid beta (Ab) peptides and amyloid plaque formation in
the cortex and hippocampus of APP/PS1 mice, which correlated with increased blood brain barrier disruption, Iba-
1-positive microglia, and CD45-positive microglia/macrophages. In contrast, CIA reduced vessel density and length
with features of microvascular pathology, including vascular segments, thinner vessels, and atrophic string vessels.
Conclusions: The present findings suggest that RA may exert beneficial effects against Ab burden and harmful
effects on microvascular pathology in AD.
Background
Alzheimer’s disease (AD) is characterized by extracellu-
lar Ab deposition, intracellular neurofibrillary tangles,
neuronal loss, and cerebral microvascular pathology,
resulting in progressive learning and memory deficits
[1-3]. Extensive evidence supports a dynamic role for
inflammation in the AD pathogenesis. Microglia, the
macrophages that reside in the central nervous system,
are activated around Ab deposits in the brains of AD
patients [4]. Levels of inflammatory mediators including
TNF-a and C-reactive protein (CRP) are also increased
in the peripheral blood of AD patients [5,6] and asso-
ciated with increased risk of AD [7,8]. Activated micro-
glia/macrophages derived from the brain and blood
produce chemokines, cytokines, and free radicals, which
participate in Ab plaque formation and the neurodegen-
erative process in AD [9-13].
Several epidemiological studies have demonstrated
that the relative risk of AD is significantly reduced in
rheumatoid arthritis (RA) patients treated with nonster-
oidal anti-inflammatory drugs (NSAIDs) for longer than
2 yrs [14,15]. In meta-analysis of 17 epidemiological stu-
dies, protective effects of arthritis and anti-inflammatory
drugs have been observed against AD [15]. These stu-
dies have raised the hypothesis that anti-inflammatory
drug treatment protects against AD, but arthritis or RA
itself could modulate AD risk. Cyclooxygenase-2 (COX-
2), an inducible cyclooxygenase known to mediate
inflammation in RA and AD, has been proposed as a
positive regulator for amyloid plaque formation and cog-
nitive deficit in AD. In support of this hypothesis,
administration of ibuprofen, a mixed COX-1/COX-2
inhibitor, reduces microglial activation, Ab production,
plaque burden, and cognitive impairment in Tg2576
mice [16,17]. Amyloid plaque formation is enhanced in
APP/PS1 mice overexpressing human COX-2 [18].
However, the beneficial effects of NSAIDs have not
been verified in randomized, double-blind, placebo-
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any medium, provided the original work is properly cited.controlled clinical trials for AD patients [19]. In such
clinical trials, NSAIDs were administered for less than 1
yr due to increased risk of acute myocardial infarction
in patients receiving NSAIDs for longer than 18 months
[20]. In a recent report from Alzheimer’s disease anti-
inflammatory prevention trial (ADAPT) with NSAIDs,
treatment of asymptomatic individuals with naproxen
for 2 yr was shown to reduce incidence of AD after 2 to
3 yr [21]. Therefore, the preventive and disease-modify-
ing potential of NSAIDs remains to be determined in
AD patients treated with NSAIDs for a long period of
time (>2 yrs).
In a recent study, amyloid plaque formation and cog-
nitive impairment were reduced in AD mice that were
subjected to subcutaneous administration of granulo-
cyte-macrophage colony-stimulating factor (GM-CSF),
an inflammatory cytokine shown to increase in RA, for
20 d [22]. Combined with findings from epidemiological
studies indicating that the incidence of AD is reduced in
RA patients with prolonged NSAID treatment, RA is
expected to directly modulate AD onset and progres-
sion. To examine this hypothesis, 2-month-old APP/PS1
mice were injected with bovine type II collagen (CII) in
complete Freund’s adjuvant (CFA), which has been
widely used to induce RA in rodents [23]. Ab burden,
microglia/macrophages, and cerebral vascular pathology
were investigated in APP/PS1 mice 4 months after the
injections of CII in CFA to determine whether RA
directly modulates amyloidosis and microvascular
pathology in AD.
Results
Induction of collagen-induced arthritis (CIA) in APP/PS1
mice
APP/PS1 mice and wild-type littermates injected with
CII in CFA revealed pathologic features of RA. Paw
swelling and redness of the joint were manifest imme-
diately after the second immunization, reached a peak
1 month later, and significantly persisted over the next
4 months when animals were sacrificed (Figure 1A, P
< 0.05). In contrast to CIA induced paw swelling in all
four paws in DBA/1 mice [23], paw swelling was con-
fined to the injection site in wild-type and APP/PS1
mice. Plasma levels of the pro-inflammatory cytokines
IL-1b and TNF-a were increased within 1 d after the
second immunization and re m a i n e de l e v a t e do v e rt h e
next 4 weeks in wild-type and APP/PS1 mice (Figure
1B, P <0.05). Paraffin-embedded joint sections stained
with hematoxylin and eosin revealed severe bone ero-
sion, cartilage/chondrocyte degradation, and prolifera-
tive synovitis in wild-type (Figure 1C) at 4 months
after the second immunization. Such joint pathology
was similar in APP/PS1 mice treated with CIA (data
not shown).
Effects of CIA on amyloid plaque pathology in APP/PS1
mice
We examined the effect of CIA on Ab deposition in
APP/PS1 mice. APP/PS1 mice received CII in CFA at 2
months of age before Ab deposition was evolved. When
Ab deposition was analyzed 4 months after CIA, levels
of Ab deposition were moderate in APP/PS1 mice [24].
Ab plaques were widespread in the cerebral cortex and
hippocampus of 6-month-old APP/PS1 mice (Figure
2A). Contrary to expectations, CIA substantially reduced
Ab plaque accumulation in APP/PS1 mice. Image analy-
sis of Ab deposition showed that Ab plaques that were
positive for 4G8 or thioflavine-S were significantly
reduced in the cerebral cortex and hippocampus of 6-
month-old APP/PS1 mice treated with CIA, compared
with vehicle-treated APP/PS1 mice (Figure 2B). The
effect of CIA on Ab levels was analyzed in the opposite
hemisphere using an ELISA that detects SDS-soluble
and SDS-insoluble Ab 40 and Ab 42. Levels of soluble
Ab 40 and Ab 42 appeared reduced by 48% (P = 0.056)
and 20% (P = 0.026) in APP/PS1 mice 4 months after
CIA, respectively, compared with vehicle-treated APP/
PS1 mice. APP/PS1 mice treated with CIA revealed sub-
stantially significant reduction in levels of insoluble Ab
40 and Ab 42 (Figure 2C, P < 0.05).
Enhanced activation of microglia/macrophage in APP/PS1
mice 4 months after CIA
CIA-induced systemic inflammation likely triggers brain
inflammation that contributes to internalization and
degradation of Ab through activated microglia. Iba-1 or
Mac-1-immunoreactive microglial cells were observed in
the brains of wild-type mice and increased in the brains
of APP/PS1 mice at 6 months of age (Figure 3A).
Immunoreactive Mac-1 positive cells were transiently
increased in the cortex and hippocampus of wild-type
mice over the course of 1 d after the second immuniza-
tion injection. However, by 2 weeks after CIA Mac-1
immunoreactivity had returned to levels that were com-
parable to the levels in vehicle-injected mice (Additional
file 1). In APP/PS1 mice treated with CIA, the number
of Iba-1 or 1-immunoreactive cells in the cerebral cortex
and hippocampus increased 4 months later. CD45-posi-
tive activated microglia or macrophages were not
observed in wild-type mice at 4 months after CIA (Fig-
ure 3A). Activated microglia or macrophages were
observed in the cortex of 6-month-old APP/PS1 mice
and increased in the cerebral cortex and hippocampus
of APP/PS1 mice treated with CIA up to approximately
210% (the number of CD45-immunoreactivity) and
230% (the area of CD45-immunoreactivity) (Figure 3A,
B, P < 0.05). Immunoreactivity to IL-1b and TNF-a was
increased in microglia and astrocytes in the molecular
layer of the dentate gyrus of APP/PS1 mice compared
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Figure 1 Characterization of collagen-induced arthritis (CIA) in wild-type and APP/PS1 mice.( A) Wild-type (Tg-) and APP/PS1 (Tg+) mice
were subjected to injection with vehicle (Tg-vehicle, n = 16; Tg+ vehicle, n = 14), or with CII in CFA (Tg-CIA, n = 18; Tg+ CIA, n = 22) to induce
CIA. Edema was observed at the right hind paw, which received the second injection of CII in CFA and was measured at indicated time points
after injection. *, significant difference from relevant control. (B) ELISA of plasma IL-1b and TNF-a over 4 weeks after second injection with
vehicle or CII in CFA in wild-type mice (n = 6 per group). (C) Bright-field photomicrographs showing ankle joints stained with hematoxylin and
eosin in 6-month-old wild-type mice treated with vehicle (top row) or CIA (bottom row): left, low power of ankle joint (Arrows, bone; Scale bar
= 2 mm); middle, high power of cartilage (Arrow heads, chondrocyte; Scale bar = 50 μm); right, high power of synovium (Scale bar = 200 μm).
Note severe bone erosion, degradation of cartilage and chondrocytes, and intensive proliferation of synovial tissue in ankle joint 4 months after
injection of CIA.
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Figure 2 CIA reduces amyloid plaque burden in APP/PS1 mice.( A) Bright field photomicrographs of brain sections showing amyloid
plaques immunolabeled with 4G8 in 6-month-old wild-type mice (Tg-vehicle) and APP/PS1 mice treated with vehicle (Tg+ vehicle) or CIA (Tg+
CIA). Scale bar = 2 mm. (B) Plaque burden was analyzed by measuring areas positive for 4G8 (Tg+ vehicle, n = 3; Tg+ CIA, n = 4) or thioflavine-S
(Tg+ vehicle, n = 7; Tg+ CIA, n = 8). (C) ELISA of soluble and insoluble forms of Ab40 and Ab42 in combined cortical and hippocampal tissues
(Tg+ vehicle, n = 7; Tg+ CIA, n = 8).
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Figure 3 CIA enhances activation of microglia/macrophages in APP/PS1 mice.( A) Photomicrographs of the dentate gyrus molecular layer
immunolabeled with antibodies against Iba-1, Mac-1, CD45, IL-1b, and TNF-a 4 months after injection of 2-month-old wild-type (Tg-) and APP/
PS1 mice (Tg+) with vehicle or CIA. SLM, stratum lacunosum molecular; Mol, dentate gyrus molecular layer. Scale bar = 50 μm. (B) Activation of
microglia/macrophages was analyzed by measuring the area and the number of CD45-immunoreactivity in the hippocampal and cortical regions
(Tg+ vehicle, n = 3; Tg+ CIA, n = 4). (C) Fluorescence photomicrographs showing Iba-1 and CD45 signal around 4G8-positive amyloid plaques in
the cortex of CIA-treated APP/PS1 mice. Top row, triple staining with Iba-1, 4G8, and DAPI (a nuclear marker); bottom row, triple staining with
CD45, 4G8, and DAPI. Scale bar = 200 μm.
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Page 5 of 12to wild-type as previously reported [25-27]. CIA further
increased expression of IL-1b and TNF-a in APP/PS1
mice (Figure 3A). In CIA-treated APP/PS1 mice, Iba-1-
positive or CD45-positive cells were observed adjacent
to Ab plaques (Figure 3C).
Effects of CIA on permeability of the blood-brain barrier
(BBB) in APP/PS1 mice
CIA has been shown to increase BBB permeability in
DBA/1 mice [28]. CIA likely causes the infiltration of
monocytes and activation of microglia/macrophages
that contribute to clearance of Ab peptide in APP/PS1
mice [29]. Immunoreactivity to a macrophage mannose
receptor (CD206) antibody was observed sparsely in
the perivascular and leptomeningeal regions of wild-
type and APP/PS1 mice. CD206-positive macrophages
were increased in the vicinity of vessels in wild-type
and APP/PS1 mice subjected to CIA (Figure 4A), sug-
gesting the possibility that CIA induces the migration
of macrophages into the brain parenchyma through
the disrupted BBB. In support of this hypothesis, levels
of immunoglobulin G (IgG) were significantly
increased in the brains of wild-type and APP/PS1 mice
1.5 and 4 months after CIA compared with relevant
vehicle (Figure 4B and 4C).
CIA induces cerebral microvascular pathology in APP/PS1
mice
Finally, we examined whether CIA would cause cerebro-
vascular pathology. Cerebral microvessels were immuno-
labeled with an anti-collagen type IV antibody, a marker
of the endothelial basement membrane. CIA signifi-
cantly reduced vascular density and length in the cere-
bral cortex and hippocampus of APP/PS1 mice 4
months later (Figure 5, A and 5B). CIA also induced
cerebral microvascular pathology, such as vascular seg-
ments and atrophic string vessels (Figure 5C). At 4
months after the injection procedure, survival of vehi-
cle-treated APP/PS1 mice was approximately 93.3%,
while the survival of CIA-treated mice was reduced to
76.9% (Additional file 2).
Discussion
Administration of CII in CFA produces features of RA
including joint swelling, bone and cartilage degenera-
tion, synovitis, and infiltration of inflammatory cells at
the injection sites accompanied by sustained elevation of
IL-1b and TNF-1b in plasma of wild-type and APP/PS1
mice. CIA reduces levels of Ab and plaque burden in
the cortex and hippocampus of APP/PS1 mice. The
reduced amyloidosis is associated with BBB disruption
and activation of microglia/macrophage. In contrast to
the clearance of Ab plaques, CIA enhances microcereb-
ral pathology and mortality in APP/PS1 mice.
Inflammation can reduce amyloidosis and cognitive
deficit in transgenic mouse models of AD. Amyloid pla-
que formation is enhanced in APP/PS1 mice overexpres-
sing human COX-2, the inducible isoform of
cyclooxygenase that is essential for prostaglandin E2
(PGE2)-mediated inflammation [30]. Chronic adminis-
tration of ibuprofen, a mixed COX-1/COX-2 inhibitor,
prevents microglial activation, and reduces levels of
inflammatory cytokines, Ab, and amyloid plaque forma-
tion in Tg2576 mice [16,17,31]. The administration of
COX-2 inhibitors prevents Ab-mediated suppression of
long-term plasticity and improves synaptic plasticity in
Tg2576 [18]. COX-2-mediated PGE2 production can
enhance amyloidosis by reducing the phagocytic func-
tion of microglia and stimulating Ab production
through activation of the prostaglandin E2 and E4
receptors [32,33].
Several lines of evidence suggest that inflammation
negatively regulates amyloidosis and cognitive deficit in
transgenic mouse models of AD. Overexpression of
TGF-b1 or IL-6 reduces amyloid plaque formation
through microglial activation in Tg2576 and TgCRND8
mice [34,35]. Administration of G-CSF or M-CSF
induces brain inflammation and ameliorates amyloid
pathology and cognitive deficit in transgenic AD mice,
including Tg 2576 [36,37]. The intracerebral infection of
Borna disease virus, which induces microglial cell activa-
tion, also reduces amyloid plaque formation in Tg2576
mice [38]. Furthermore, overexpression of soluble com-
plement receptor-related protein y, a complement inhi-
bitor, reduces microglial activation, produces
neurodegeneration, and enhances Ab production and
accumulation in human amyloid precursor protein
transgenic mice bearing the amyloidogenic K670M,
N671L, and V717F mutations [39].
Ab produced in the brains of APP/PS1 mice or AD
patients induces the expression and secretion of chemo-
tactic cytokines, such as monocyte chemotactic protein
1, which enhances the transmigration and differentiation
of monocytes from the bloodstream [40-42]. Circulating
monocytes are increased in CIA-treated mice or RA
patients, and are expected to transmigrate through the
BBB into the brain areas exposed to Ab.T h eb r a i n
monocytes can be differentiated into macrophages by
cytokines such as M-CSF and IL-6, which are induced
by Ab or after CIA [35,43-47]. Macrophages and acti-
vated microglia contribute to Ab clearance. Alterna-
tively, CIA may reduce the Ab plaque burden by
increasing passive transport to the periphery through
increased BBB disruption.
Ab accumulation in the cerebral vessel triggers BBB
disruption by reducing the expression of tight junction
proteins such as occludin, claudin-5, and zona occludins-
1[48]. Ab can induce oxidative stress, mitochondrial
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Figure 4 CIA enhances macrophages at the leptomeningeal and perivascular regions and BBB permeability in APP/PS1 mice.( A)
Fluorescence photomicrographs of cortical areas immunolabeled with rat monoclonal anti-CD206 4 months after injection of 2-month-old wild-
type (Tg-) and APP/PS1 (Tg+) mice with vehicle or CIA. Note increased leptomeningeal (top row) and perivascular (bottom row) macrophages in
Tg- and Tg+ mice treated with CIA. Scale bar = 200 μm. (B) Western blot of IgG in combined cortical and hippocampal samples 4 months after CIA
injection into Tg- and Tg+ mice. (C) IgG levels were analyzed 1.5 months (Tg- vehicle, n = 3; Tg- CIA, n = 3; Tg+ vehicle, n = 3; and Tg+ CIA, n =4 )
and 4 months after vehicle or CIA injection into Tg- and Tg+ mice (Tg- vehicle, n = 3; Tg- CIA, n = 4; Tg+ vehicle, n = 4; and Tg+ CIA, n = 4).
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Page 8 of 12dysfunction, and the activation of caspase-dependent
apoptotic pathways, possibly through mechanisms invol-
ving interaction with RAGE, resulting in endothelial cell
degeneration [48-50]. In the present study, we provide
evidence that CIA-treated APP/PS1 mice develop vascu-
lar segments and atrophic string vessels characteristic of
cerebrovascular pathology observed in AD patients.
Alzheimer’s disease is occasionally accompanied by
epileptic seizures [51]. Cortical and hippocampal sei-
zures are detected in three different APP transgenic
mice models of AD [52]. Seizures are frequently
o b s e r v e di nA P P / P S 1m i c ea t3a n d4 . 5m o n t h so fa g e
and correlated with mortality that peaks at 3 to 4
months of age [53]. In the present study, two APP/PS1
mice died at 3 to 4 months of age (6.7% mortality). In
thirty nine APP/PS1 mice treated with CIA, nine mice
died at 3 to 4 months of age (23.1% mortality). There-
after, no death was observed. Thus, CIA may increase
mortality of APP/PS1 mice by enhancing seizures, which
is likely related with sustained inflammation and
enhanced cerebrovascular pathology.
While further study is needed to delineate mechanisms
underlying the effects of CIA on vascular pathology, ele-
vated monocytes and neutrophils in CIA-treated APP/PS1
mice likely migrate to the cerebral vessel, release cytotoxic
molecules such as superoxide, matrix metalloproteases,
and TNF-a, and then contribute to endothelial cell degen-
eration and mortality in a cooperative way with Ab.
Recently, systemic administration of lipopolysaccharide for
6 weeks was shown to induce sustained microglial activa-
tion and tau hyperphosphorylation in the hippocampus of
3 XT g - A Dm i c eh a r b o r i n gt h r e em u t a n th u m a ng e n e s
(APPK670N;M671L,P S 1 M146V,a n dt a u P301L) [54]. Consider-
ing that lipopolysaccharide triggers systemic inflammation
and BBB disruption, CIA may exacerbate tau pathology as
well as vascular pathology in AD.
Conclusions
CIA induced before the onset of amyloid pathology
reduces Ab burden over 4 months in APP/PS1 mice, pre-
sumably by enhancing the clearance and efflux of Ab.
However, such beneficial effects of CIA are accompanied
by enhanced microvascular pathology and mortality. The
present findings suggest that transient systemic inflam-
mation may be beneficial in lowering Ab burden; how-
ever, the chronic systemic inflammation demonstrated in
RA is a serious risk factor for cerebral microvascular
pathology and hypoperfusion in AD, which likely lead to
neurodegeneration and cognitive deficit.
Methods
Animal Preparation
All experiments were performed in accordance with
the Guideline for Animal Experiments of Ajou
University and GNT Pharma. APP/PS1 mice
(APPswe/PS1dE9) were purchased from the Jackson
Laboratory (Bar Harbor, ME, USA). These mice were
generated by co-injection of chimeric APPswe
(K595N, M596L) and an exon-9-deleted PS1 variant
(dE9) vector controlled by a mouse prion promoter
[55]. Male APP/PS1 transgenic mice were cross-bred
with B6C3F1/J background females. APP/PS1 mice
(Tg+) and wild-type littermates (Tg-) were determined
by PCR analysis of tail DNA.
Induction of CIA
Bovine CII (Chondrex, Redmond, WA, USA) was dis-
solved in 0.1 M acetic acid at a 4 mg/ml by stirring
overnight at 4°C, added to an equal volume of CFA
(Chondrex), and homogenized as described previously
[23]. To induce CIA, 2-month-old female Tg+ and Tg-
mice were injected intradermally at the tail base with
0.1 ml CII in CFA or 0.1 ml mineral oil as a vehicle.
The animals received another injection of CII in CFA or
mineral oil at the right hind paw 14 d after the primary
immunization. Paw edema was measured using a
plethysmometer (Ugo Basile, Comerio, Italy) monthly
after the second immunization. After 4 months, 6-
month-old mice were sacrificed and examined for AD
pathogenesis on the basis of amyloid plaques and cere-
brovascular pathology.
Analysis of plasma IL-1b and TNF-a
Plasma cytokine levels were analyzed at various time
points after the secondary injections of CII in CFA.
Blood was collected via cardiac puncture and then
transferred into a heparin-coated tube (Becton Dickin-
son, USA). The tube was placed on ice and centrifuged
at 5000 rpm (1500 g) for 3 min. The supernatant was
collected and stored at -80°C. Plasma levels of IL-1b
and TNF-a were measured with a commercial ELISA
kit (Biosource, Camarillo, CA, USA) according to the
manufacturer’s instructions.
Tissue preparation
Animals were anesthetized with an intraperitoneal injec-
tion of chloral hydrate (400 mg/kg) and transcardially
perfused with 0.9% NaCl. The right hind paw injected
with CII in CFA was removed, fixed in 10% formalin
solution at 4°C for 24 h, and decalcified in 10% EDTA
solution at 4°C for 3 weeks. The tissues were then
embedded in paraffin and cut into 8-μm-thick sections.
The right brain hemisphere was immersion-fixed with
4% paraformaldehyde for 24 h, cryoprotected in 30%
sucrose for 48 h, and cut into 18-μm-thick coronal cryo-
sections. The hippocampal formation and cortex were
dissected out from the left hemisphere and frozen at
-80°C for protein assay.
Park et al. BMC Neuroscience 2011, 12:106
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Combined cortical and hippocampal tissues were homo-
genized in 0.5 ml Tris-buffered saline (TBS) containing
protease inhibitor cocktail (Calbiochem, San Diego, CA,
USA) and centrifuged at 14,000 rpm for 30 min at 4°C.
The supernatant was collected and stored at -80°C for
Western blot analysis of IgG. The pellet was sonicated
in 0.5 ml of 2% SDS in TBS and centrifuged at 14,000
r p mf o r4 0m i na t4 ° C .T h es u p e r n a t a n tw a su s e df o r
analysis of soluble Ab. For analysis of insoluble Ab,t h e
pellet was sonicated with 0.5 ml 70% formic acid in
water and then neutralized by 1:40 dilution into 1 M
Tris-phosphate buffer (pH 11.0). Levels of Ab 40 and
Ab 42 were analyzed using an ELISA kit (Biosource,
Camarillo, CA, USA) according to the manufacturer’s
instructions.
Immunohistochemistry
Brain sections were washed in phosphate-buffered sal-
ine, incubated in washed in 0.3% H2O2 and 0.25% Tri-
ton X-100 for 10 min at room temperature, and reacted
with 10% horse serum for 1 h. Sections were then
reacted overnight at 4°C with one of the following pri-
mary antibodies: mouse monoclonal anti-4G8 (1:1000,
Signet), rat monoclonal anti-CD45 (1:500, Serotec), rab-
bit polyclonal anti-Iba-1 (1:1000, WAKO), rat monoclo-
nal anti-Mac-1 (1:500, Serotec), goat polyclonal anti-IL-
1b (1:200, R&D), goat anti-polyclonal anti-TNF-a
(1:200, R&D), rat monoclonal anti-CD206 (1:500, Sero-
tec), and rabbit polyclonal anti-collagen type IV (1:500,
Millipore). For 4G8 immunostaining, sections were pre-
treated with 70% formic acid for 10 min to expose the
Ab epitope. The sections were reacted with anti-mouse,
anti-rat, or anti-rabbit IgG fluorescent or biotin-conju-
gated (Vector, Burlingame, CA, USA) secondary anti-
body for 2 h. The biotin-labeled sections were incubated
with avidin-biotin-peroxidase complex (ABC Elite kit,
Vector) for 1 h and then visualized using 3,3’-diamino-
benzidine tetrahydrochloride dehydrate (DAB, Vector).
Image analysis of amyloid plaque burden, activated
microglia/macrophages, and vascular pathology
Brain sections containing the hippocampal formation
and cortex were immunolabeled with an antibody to
4G8 (amyloid plaque burden), CD45 (activated micro-
glia/macrophage), or collagen type IV (vascular pathol-
ogy). To identify amyloid plaques using thioflavine-S
staining, the brain sections were incubated in 1% aqu-
eous thioflavine-S (Sigma) for 10 min, followed by dehy-
dration with 70% ethyl alcohol, and coverslipped with
mounting medium. Three sections on the anatomically
comparable plane for each animal were analyzed using
MetaMorph 6.1 software (Universal Imaging Corp,
Downingtown, PA, USA). The immunostained sections
were captured using an Olympus BX 51 microscope
(Olympus, Japan) at a magnification of 200×. The areas
positive for 4G8, thioflavine-S, or CD45 in the hippo-
campal formation and cortex were subtracted from non-
specific signal from the same section and scaled to the
vehicle group (= 100). The vascular pathology was ana-
lyzed in the area including the CA1 pyramidal layer and
cortex by measuring vessel density and length immuno-
labeled with collagen type IV.
Western blotting
BBB permeability was investigated by monitoring levels
of IgG. Combined cortical and hippocampal samples
(see above) were electrophoresed on an 8-10% SDS
polyacrylamide gel and transferred to a nitrocellulose
membrane. The membrane was pre-incubated with 5%
nonfat dry milk and reacted with a biotinylated anti-
mouse lgG (1:500, Vector) overnight at 4°C. The mem-
brane was then reacted with avidin-biotin-peroxidase
complex (ABC Elite kit, Vector) for 2 h and then with
enhanced chemiluminescence reagents (Amersham,
Buckinghamshire, UK) on X-ray film. Band intensity was
quantified using Image Gauge 3.12 (Fuji PhotoFilm Co).
The blot was stripped and probed with rabbit polyclonal
anti-actin (1:1000, Sigma) to normalize the protein load
among samples.
Statistical analysis
All values are expressed as mean ± S.E.M. An indepen-
dent-samples t-test was used to compare two samples.
Analysis of variance (ANOVA) and the Student-New-
man-Keuls test were used for multiple comparisons. All
analyses were calculated using SPSS version 12.0 for
Windows. Statistical significance was assumed at P <
0.05.
Additional material
Additional file 1: Figure S1 - Transient increase of microglial cell
proliferation in wild-type mice treated with CIA. Photomicrographs of
the dentate gyrus molecular layer immunolabeled with Mac-1 after
second injection of CII in CFA in 2-month-old wild-type mice. The
number of Mac-1-immunoreactive microglial cells was increased within 1
d after second injection of CII in CFA. This increase remained for over 1
wk, but disappeared within 2 wks (n = 4 per group). Scale bar = 200 μm.
Additional file 2: Figure S2 - CIA increases mortality in APP/PS1
mice. Survival analysis of wild-type (Tg-) and APP/PS1 (Tg+) mice treated
with vehicle or CIA at 2 months of age (Tg-vehicle, n = 30; Tg-CIA, n =
34; Tg+ vehicle, n = 30; and Tg+ CIA, n = 34).
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